



Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i)	Paola Rogliani
Indirizzo(i)	Via Montpellier, 1 00133, Roma, Italia.
Telefono(i)	+39-0620904656
E-mail	paola.rogliani@uniroma2.it
Cittadinanza	<b>Italiana</b>
Stato Civile	Coniugata
Sesso	<b>F</b>
Occupazione attuale	<p>Professore Associato Malattie dell'Apparato Respiratorio MED10 "Dipartimento di Medicina Sperimentale Università degli Studi di Roma "Tor Vergata";</p> <p>Direttore UOC di Malattie dell'Apparato Respiratorio" Dipartimento di Emergenza Policlinico Tor Vergata, Viale Oxford, 81. Roma;</p> <p><b>Direttore Scuola di Specializzazione Malattie dell'Apparato Respiratorio</b> Università degli Studi di Roma "Tor Vergata";</p>

Principali attività e responsabilità	1989- 1991	Interna presso Cattedra di Biochimica, Dipartimento di Biochimica e Biofisica "F. Cetrangolo" della Seconda Università degli studi di Napoli diretta dal Prof. Gennaro Della Pietra.
	01/1997- 12/1998	Visiting Fellow presso la <b>Pulmonary and Critical Care Medicine Branch</b> , presso l'NHLBI dell'National Institute of Health (NIH) Bethesda, MD –USA- diretta dal Dr. Joel Moss.
	12/1998- 08/2000	Visiting Fellow presso il " <b>Laboratory of Molecular Immunology</b> ", presso l'NHLBI dell'National Institute of Health (NIH) Bethesda, MD –USA- diretto dal Dr Warren J Leonard.
	2000- 2012	Ricercatore nel gruppo disciplinare MED10 presso la cattedra di "Malattie dell'Apparato Respiratorio", Dipartimento di Medicina dei Sistemi, Università degli studi di Roma "Tor Vergata".
	2012- <i>presente</i>	Prof Associato nel gruppo disciplinare MED10 "Malattie dell'Apparato Respiratorio", Dipartimento di Medicina dei Sistemi, Università degli studi di Roma "Tor Vergata".
	<b>ATTIVITÀ CLINICA</b>	
	12/ 2000- 07/2003	Attività assistenziale in qualità di Dirigente medico di I livello presso il Reparto, Ambulatorio e DH di Malattie dell' Apparato Respiratorio della Divisione clinicizzata di Malattie Respiratorie, Università degli studi di Roma "Tor Vergata", presso l'IRCCS "L. Spallanzani" Roma. (1/2003- 06/2004) Responsabile del <b>Day-Hospital dedicato allo Studio delle interstiziopatie Polmonari</b> presso la Divisione clinicizzata di Malattie Respiratorie, Università degli studi di Roma "Tor Vergata", presso l'IRCCS "L. Spallanzani" Roma.
	7/2004- 2007	Responsabile del <b>Servizio Consulenze Pneumologiche</b> della Disciplina di Malattie Respiratorie, AFA di Medicina, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata"
	11/2007- 11/2011	Responsabile del <b>Day-Hospital dedicato allo Studio delle Interstiziopatie Polmonari</b> e dell' <b>ambulatorio della "Fibrosi polmonare e malattie rare"</b> della UOC di Malattie Respiratorie"
	12/2011- 09/2013	Responsabile del <b>Reparto</b> di Malattie dell'Apparato Respiratorio della UOC di Malattie Respiratorie Policlinico Tor Vergata, Roma
	1/2006- 10/2015	Responsabile dell'Unità Operativa Semplice (UOS) di " <b>Endoscopia Respiratoria</b> " della UOC di Malattie Respiratorie, Dipartimento di Medicina, "Policlinico Tor Vergata"
	11/2015- <i>presente</i>	Direttore <b>UOC di Malattie Respiratorie</b> , Dipartimento di Emergenza, "Policlinico Tor Vergata"

Istruzione e formazione

Luglio 1988 Maturità Classica con il massimo dei voti.  
 Ottobre 1994 Laurea in Medicina e Chirurgia, Università degli studi di Roma "Tor Vergata" con 110/110 e lode.  
 Dicembre 1994 Abilitazione all'esercizio della professione medico-chirurgica nella II sessione, Seconda Università degli studi di Napoli con 90/90.  
 Novembre 1998 Specializzazione in "Malattie dell'Apparato Respiratorio", Università degli studi di Roma "Tor Vergata" con 50/50 e lode.  
 Gennaio 1999 Borsa di Studio di Perfezionamento all'estero-legge 398/89-area disciplinare gruppo B (Scienze Mediche Applicate), gendic1999.  
 Nov 2018/Mar 2019 Leadership e Management delle Malattie Respiratorie Lung Academy-Track Management . SDA Università Commerciale L. Bocconi

- Dichiaro di avere esperienza in studi clinici condotti secondo GCP

**MEMBERSHIP**

1. • European Respiratory Society (ERS)
2. • Società Italiana di Medicina Respiratoria (SIMeR), scientific secretariat Gruppo Clinica mandatO 2016/2018
3. • Società Italiana di Pneumologia (SIP/IRS), scientific president Gruppo BPCO e comorbilità mandat0 2019/2021

**PREMI**

2010 Award for Best researcher under 40, XI Congresso Italiano di Pneumologia

**COMITATI EDITORIALI**

**Member of the Editorial Board** of : "International Journal of Chronic Obstructive Pulmonary Disease", "ARS pneumologica", "COPD Research and Practice", "Journal of Pulmonology and Respiratory Research" .  
**Associate Editor:** "Pulmonary Pharmacology and Therapeutics", "BMC Pulmonary Medicine".

**LINGUE Livello europeo (\*)**

INGLESE  
 Francese  
 Spagnolo

Comprensione		Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale	
	C1		C1		C1		C1
	B2		B2		B2		B1
	A2		A2		A2		A1

**Allegati**

Allegato 1: Pubblicazioni  
 Allegato 2:Attività Didattiche

Allegato 1:  
PUBLICATIONS:

1. Maione F, Iaccarino F, Sirignano M, Rogliani P, Della Pietra F. "Studio di una variante di  $\alpha 1$ - Antitripsina". *Acc. Di Scienza Mediche e Chirurgiche (Vol CXL VII feb. 1993)*
2. Rossi P. - Senis L. - Contini A. - Nardecchia B. - Rogliani P. - Bisogni V. - Rossi S. "Osservazioni clinico-epidemiologiche sulla tubercolosi polmonare nei pazienti extracomunitari ricoverati". *Igiene e Sanità Pubblica*, vol. 52, n. 4, luglio-agosto 1996, pp. 271-280.
3. Di Nardo P, Fiaccavento R, Natali A, Minieri M, Sampaolesi M, Fusco A, Janmot C, Cuda G, Carbone A, Rogliani P, Peruzzi G. "Embryonic gene expression in nonoverloaded ventricles of hereditary hypertrophic cardiomyopathic hamsters". *Lab Invest.* 1997 Nov;77(5):489-502.
4. Mineo TC, Pompeo E, Simonetti G, Sabato AF, Turani F, Rogliani P, De Padova F, Nofroni I. "Unilateral thoroscopic reduction pneumoplasty for asymmetric emphysema". *Eur J Cardiothor Surg.* 1998 Jul;14(1):33-9.
5. Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. "Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency". *Am J Respir Cell Mol Biol.* 1999 Mar;20(3):441
6. Mineo TC, Pompeo E, Rogliani P, Villaschi S, Pistolese C, Simonetti G. "Thoroscopic reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?" *Thorac Cardiovasc Surg.* 1999 Oct;47(5):288-92.
7. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. "Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298". *Proc Natl Acad Sci U S A.* 2000 Mar 14;97(6):2832-5
8. Mineo TC, Pompeo E, Rogliani P, Dauri M, Turani F, Bollero P, Magliocchetti N. "Effect of lung volume reduction surgery for severe emphysema on right ventricular function". *Am J Respir Crit Care Med.* 2002 Feb 15;165(4):489-94.
9. Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, Dweik R, Saltini C. "HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells". *Eur Respir J.* 2002 Nov;20(5):1174-8.
10. Rogliani P, Amicosante M, Berretta F, Dotti C, Bocchino M, O'Donnell KM, Saltini C. Role of the HLA-DP glu 69 and the TNF alpha TNFalpha2 gene markers in susceptibility to beryllium hypersensitivity. *Int J Immunopathol Pharmacol.* 2004 May-Aug;17(2 Suppl):3-10
11. Dotti C, D'Apice MR, Rogliani P, Novelli G, Saltini C, Amicosante M. Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity. *Sarcoidosis Vasc Diffuse Lung Dis.* 2004 Mar;21(1):29-34
12. Pompeo E, Mineo D, Bollero P, Rogliani P, Ambrogi V, Mineo TC. Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy? *J Thorac Cardiovasc Surg.* 2004 Apr;127(4):1212-4.
13. Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake thoroscopic resection of solitary pulmonary nodules. *Ann Thorac Surg.* 2004 Nov;78(5):1761-8

14. Mineo TC, Pompeo E, Mineo D, Rogliani P, Leonardis C, Nofroni I. Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs. *J Thorac Cardiovasc Surg.* 2005 Jan;129(1):73-9
15. Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, Saltini C. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGLubeta69. *Respir Res.* 2005 Aug 14;6:94.
16. Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. *Trends Pharmacol Sci.* 2007 Oct;28(10):544-50.
17. Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. *Respir Med.* 2008 Mar;102(3):321-7.
18. Rogliani P, Mura M, Porretta MA and Saltini C. New perspectives in the treatment of idiopathic pulmonary fibrosis. *Therapeutic Advances in Respiratory Disease* 2008; 2; 75
19. Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A. HRCT and histopathologic evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. *Respir Med.* 2008 Dec;102(12):1753-61
20. Cazzola M, Mura M, Segreti A, Mattei MA, Rogliani P.  
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? *Allergy.* 2009 Sep;64(9):1389-90.
21. Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. *Pulm Pharmacol Ther.* 2009 Dec;22(6):478-82.
22. Cazzola M, Rogliani P, Curradi G, Segreti A, Ciapri C, Pezzuto G, Saltini C. A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. *Pulm Pharmacol Ther.* 2009 Dec;22(6):522-5.
23. Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. *Respir Med.* 2009 Nov;103(11):1592-613.
24. Rogliani P, Curradi G, Mura M, Lauro D, Federici M, Galli A, Saltini C, Cazzola M. Metabolic syndrome and risk of pulmonary involvement. *Respir Med.* 2010 Jan;104(1):47-51.
25. Ricci A, Mariotta S, Bronzetti E, Bruno P, Vismara L, De Dominicis C, Laganà B, Paone G, Mura M, Rogliani P, Mastrangello M, Sciacchitano S, Saltini C. Serum CA 15-3 is increased in pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2009 Jul;26(1):54-63.
26. Sergiacomi G, Bolacchi F, Cadioli M, Angeli ML, Fucci F, Crusco S, Rogliani P, Pezzuto G, Romeo F, Mariano E, Simonetti G. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. *Radiology.* 2010 Feb;254(2):601-8.
27. Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P.  
Asthma and comorbid medical illness. *Eur Respir J.* 2011 Jul;38(1):42-9.

28. Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. *Pulm Pharmacol Ther.* 2011 Apr;24(2):221-6.
29. Cazzola M, Segreti A, Bettoncelli G, Calzetta L, Cricelli C, Pasqua F, Rogliani P. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. *Prim Care Respir J.* 2011 Sep;20(3):291-8.
30. Pompeo E, Rogliani P, Tacconi F, Dauri M, Saltini C, Novelli G, Mineo TC; Awake Thoracic Surgery Research Group. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. *J Thorac Cardiovasc Surg.* 2012 Jan;143(1):47-54.e1.
31. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. *Respir Med.* 2012 Feb;106(2):249-56.
32. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. *Eur Respir J.* 2012 Jul;40(1):101-9.
33. Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. *Am J Respir Cell Mol Biol.* 2012 Oct;47(4):509-16.
34. Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. *Curr Opin Pharmacol.* 2012 Jun;12(3):300-8.
35. Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. *Pulm Pharmacol Ther.* 2012 Sep 21.
36. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. *Expert Opin Investig Drugs.* 2012 Oct;21(10):1489-501.
37. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. *Drugs Today (Barc).* 2012 Dec;48(12):785-94.
38. Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic Biopsy of Interstitial Lung Disease. *Ann Thorac Surg.* 2013 Feb;95(2):445-52.
39. Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. *Respir Med.* 2013 Jan;107(1):107-11.
40. Cazzola M, Segreti A, Calzetta L, Rogliani P.
- Comorbidities of asthma: current knowledge and future research needs. *Curr Opin Pulm Med.* 2013 Jan;19(1):36
41. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, Matera MG. The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. *Pulm Pharmacol Ther.* 2013 Jun;26(3):325-
42. Cazzola M, Page CP, Rogliani P, Matera MG.  $\beta$ 2-Agonist Therapy in Lung Disease. *Am J Respir Crit Care Med.* 2013 Apr 1;187(7):690-6.

43. Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. *Pulm Pharmacol Ther.* 2013 Apr 8.
44. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
45. Cazzola M, Rogliani P, Matera MG. Acclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Apr;14(6):775-81.
46. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
47. Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? *J Thorac Cardiovasc Surg.* 2013 Aug;146(2):495-7.
48. Calzetta L, Passeri D, Kanabar V, Rogliani P, Page C, Cazzola M, Matera MG, Orlandi A. Brain Natriuretic Peptide Protects Against Hyperreactivity of Human Asthmatic Airway Smooth Muscle via an Epithelial Cell Dependent Mechanism. *Am J Respir Cell Mol Biol.* 2013 Sep 27.
49. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther.* 2013 Sep;346(3):414-23.
50. Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med.* 2013 Sep;107(9):1417-22.
51. Rogliani P, Ora J, Ciapriani C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2013 Nov 5.
52. Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O<sub>2</sub> flow correcting exercise induced SpO<sub>2</sub> desaturation in ILD. *Respir Med.* 2013 Dec;107(12):2014-21.
53. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Dec;14(18):2489-99.
54. Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. *Pulm Pharmacol Ther.* 2013 Dec;26(6):630-4.
55. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
56. Cazzola M, Rogliani P, Matera MG. Acclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Apr;14(6):775-81.
57. Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? *J Thorac Cardiovasc Surg.* 2013 Aug;146(2):495-7.
58. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther.* 2013 Sep;346(3):414-23.

59. Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med.* 2013 Sep;107(9):1417-22.
60. Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. *Respir Med.* 2013 Dec;107(12):2014-21.
61. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Dec;14(18):2489-99
62. Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M.  
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2013 Nov 5.
63. Matera MG, Calzetta L, Rogliani P, Cesario A, Cazzola M. New Treatments for COPD in the Elderly. *Curr Pharm Des.* 2014 Mar 14
64. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2014 May;15(7):961-77
65. Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. *Acta Diabetol.* 2014 Apr 13
66. Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. *Expert Opin Drug Discov.* 2014 Jun;9(6):595-607. Epub 2014 Apr 22.
67. Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. *Mol Diagn Ther.* 2014 Aug;18(4):381-
68. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. *COPD.* 2014 Sep 15
69. Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? *Drugs.* 2014 Oct 10.
70. Segreti A, Calzetta L, Rogliani P, Cazzola M. Umeclidinium for the treatment of chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2014 Oct 14:1-7.
71. Matera MG, Rogliani P, Rinaldi B, Cazzola M. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol.* 2015 Jan;8(1):35-41.
72. Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2015 Jan;16(1):107-15.
73. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. *Eur J Pharmacol.* 2014 Dec 15;745:135-43
74. Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M. The clinical use of regenerative therapy in COPD. *Int J Chron Obstruct Pulmon Dis.* 2014 Dec 12;9:1389-1396. eCollection 2014.
75. Matera MG, Cardaci V, Cazzola M, Rogliani P.



Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. *Expert Opin Drug Saf.* 2015 Jan 5;1-9.

76. Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. *Pulm Pharmacol Ther.* 2015 Apr;31:15-27.

77. Matera MG, Rogliani P, Cazzola M. QVA149(indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2015 May;16(7):1079-90.

78. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. *Pulm Pharmacol Ther.* 2015 Apr 18.

79. Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A, Rinaldi B, Matera MG. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. *Life Sci.* 2015 Apr 24.

80. Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. *Eur J Pharmacol.* 2015 Aug 15;761:383-90

81. Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to asthma drugs. *Expert Opin Drug Metab Toxicol.* 2015 Jul;11(7):1089-97.

82. Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. *Pulm Pharmacol Ther.* 2015 Aug;33:1-10

83. Pompeo E, Rogliani P, Palombi L, Orlandi A, Cristino B, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). The complex care of severe emphysema: role of awake lung volume reduction surgery. *Ann Transl Med.* 2015 May;3(8):108.

84. Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. *Ann Transl Med.* 2015 May;3(8):112.

85. Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. *Respir Med.* 2015 Aug;109(8):1019-25

86. Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. *Lancet Respir Med.* 2015 Aug;3(8):593-5

87. Rogliani P, Lucà G and Lauro D. Chronic obstructive pulmonary disease and diabetes. *COPD Research and Practice* 2015 Aug;1:3 DOI: 10.1186/s40749-015-0005-y

88. Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res.* 2016 Feb;19(1):79-89

89. Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. *Expert Opin Investig Drugs.* 2015 Nov;24(11):1473-82.

90. Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol*. 2015;8(5):529-39.
91. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. *Respir Med*. 2015 Oct;109(10):1305-11.
92. Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. *Drugs*. 2015 Sep;75(14):1575-85.
93. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. *Eur Respir Rev*. 2015 Sep;24(137):451-61.
94. Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. *Drugs Today (Barc)*. 2015 Aug;51(8):469-78.
95. Liccardi G, Salzillo A, Calzetta L, Pignatti P, Rogliani P.
- Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? *Allergol Immunopathol (Madr)*. 2015 Nov 16. pii: S0301-0546(15)00121-4.
96. Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res*. 2016 Feb;19(1):79-89
97. Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. *Expert Opin Investig Drugs*. 2015 Nov;24(11):1473-82.
98. Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol*. 2015;8(5):529-39.
99. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. *Respir Med*. 2015 Oct;109(10):1305-11.
100. Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. *Drugs*. 2015 Sep;75(14):1575-85.
101. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. *Eur Respir Rev*. 2015 Sep;24(137):451-61.
102. Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. *Drugs Today (Barc)*. 2015 Aug;51(8):469-78.
103. Liccardi G, Salzillo A, Calzetta L, Pignatti P, Rogliani P.
- Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? *Allergol Immunopathol (Madr)*. 2016 Jul-Aug;44(4):387-8
104. Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. *Pulm Pharmacol Ther*. 2016 Feb;36:1-9.

105. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P.  
How many systemic reactions to skin prick tests could be preventable in defined conditions? *Ann Allergy Asthma Immunol.* 2016 Feb;116(2):174.
106. Cazzola M, Rogliani P, Ora J, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2016;17(7):977-88.
107. Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. *Chest.* 2016 May;149(5):1181-96.
108. Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. *Drug Saf.* 2016 Jun;39(6):501-8.
109. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Menna G, Rogliani P. Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. *Eur Ann Allergy Clin Immunol.* 2016 Mar;48(2):61-4.
110. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection? *J Allergy Clin Immunol.* 2016 May;137(5):1621-2.
111. Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Discov.* 2016 Jul;11(7):733-44.
112. D'Antonio S, Rogliani P, Paone G, Altieri A, Alma MG, Cazzola M, Puxeddu E. An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. *Int J Mycobacteriol.* 2016 Jun;5(2):244-7.
113. Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P. Dog allergen immunotherapy and allergy to furry animals. *Ann Allergy Asthma Immunol.* 2016 Jun;116(6):590.
114. Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. *Expert Opin Drug Saf.* 2016 Aug;15(8):1133-46.
115. Salvati, A., Ora, J., Donatucci, B., Rogliani, P. Cardiopulmonary exercise test in athletes and coronary diseases *Medicina dello Sport* 69 (2) June 2016, 289-296
116. Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, Matera MG. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. *Respir Res.* 2016 Jun 13;17(1):70.
117. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? *J Asthma.* 2016 Nov;53(9):879-81.
118. Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD. *Pulm Pharmacol Ther.* 2016 Aug;39:48-53.
119. Cazzola M, Rogliani P. Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? *J Allergy Clin Immunol.* 2016 Oct;138(4):977-983.

120. Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? *J Allergy Clin Immunol Pract.* 2016 Jul-Aug;4(4):791-3.
121. Liccardi G, Salzillo A, Piccolo A, Calzetta L, Rogliani P. Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens. *Ups J Med Sci.* 2016 Aug;121(3):196-7.
122. Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, Matera MG. Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. *Am J Respir Cell Mol Biol.* 2016 Dec;55(6):804-814.
123. Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G, Cazzola M, Matera MG. Brain natriuretic peptide: Much more than a biomarker. *Int J Cardiol.* 2016 Oct 15;221:1031-8.
124. Capuani B, Pacifici F, Pastore D, Palmirotta R, Donadel G, Arriga R, Bellia A, Di Daniele N, Rogliani P, Abete P, Sbraccia P, Guadagni F, Lauro D, Della-Morte D. The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators. *Pharmacol Res.* 2016 Sep;111:659-67.
125. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Pulm Pharmacol Ther.* 2016 Oct;40:95-103.
126. Liccardi G, Salzillo A, Calzetta L, Cazzola M, Matera MG, Rogliani P. Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. *Respir Med.* 2016 Aug;117:150-3.
127. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. *Respir Med.* 2016 Aug;117:190-7.
128. Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. *Drugs.* 2016 Sep;76(13):1257-70.
129. Liccardi G, Calzetta L, Sapio C, Rogliani P.  
Occupational allergy to horse allergens: More than exposure to horses! *Int J Occup Med Environ Health.* 2016;29(5):721-3.
130. Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P.  
Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? *Respirology.* 2016 Sep 16
131. Cazzola M, Rogliani P.  
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. *Evid Based Med.* 2016 Dec;21(6):222.
132. Rogliani P, Puxeddu E, Ciaprini C, Ora J, Onorato A, Pezzuto G, Calzetta L, Cazzola M. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. *Biomed Res Int.* 2016;2016:4547953.

133. Rogliani P, Ora J, Puxeddu E, Cazzola M. Airflow obstruction: is it asthma or is it COPD? *Int J Chron Obstruct Pulmon Dis.* 2016 Nov 30;11:3007-3013.

134. Liccardi G, Salzillo A, Calzetta L, Piccolo A, Puxeddu E, Rogliani P.

Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals? *J Investig Allergol Clin Immunol.* 2016;26(6):403-405.

135. Tacconi F, Rogliani P, Cristino B, Gilardi F, Palombi L, Pompeo E; Awake Thoracic Surgery Research Group.. Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors. *J Thorac Dis.* 2016 Dec;8(12):3704-3710

136. Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a network meta-analysis. *Ther Adv Drug Saf.* 2017 Jan;8(1):17-30

137. Liccardi G, Calzetta L, Salzillo A, Apicella G, Di Maro E, Rogliani P.

What Could the Role of Can f 5 Allergen Be in Dog-Sensitized Patients in "Real Life"? *J Investig Allergol Clin Immunol.* 2017;27(6):397-398

138. Liccardi G, Calzetta L, Salzillo A, Apicella G, Cavalli F, Rogliani P.

Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"? *J Allergy Clin Immunol Pract.* 2017 Mar - Apr;5(2):535

139. Liccardi G, Calzetta L, Salzillo A, Puxeddu E, Rogliani P.

Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects? *J Allergy Clin Immunol Pract.* 2017 May - Jun;5(3):873

140. Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. *Eur Respir Rev.* 2017 Jan 17;26(143)

141. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. *Respir Res.* 2017 Jan 24;18(1):26

142. Puxeddu E, Cavalli F, Pezzuto G, Teodori E, Rogliani P.

Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? *Eur Respir J.* 2017 Feb 23;49(2)

143. Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M. Optimizing drug delivery in COPD: The role of inhaler devices. *Respir Med.* 2017 Mar;124:6-14

144. Cazzola M, Ora J, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. *Expert Rev Respir Med.* 2017 Mar;11(3):239-253

145. Liccardi G, Calzetta L, Salzillo A, Billeri L, Lucà G, Rogliani P.

Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience. *Eur Ann Allergy Clin Immunol.* 2017 Mar;49(2):92-96

146. Pica F, Ciotti M, Maurici M, Buè C, Nardi P, Lucà G, Moroni G, Rogliani P, Perno CF, Volpi A. Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract. *New Microbiol.* 2017 Apr;40(2):107-112

147. Calzetta L, Puxeddu E, Rogliani P.

Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine. *EBioMedicine.* 2017 May;19:14-15

148. Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, Matera MG. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. *Drugs.* 2017 May;77(7):721-732.

149. Liccardi G, Calzetta L, Salzillo A, Apicella G, Croce G, Rogliani P.

Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? *Allergy Asthma Proc.* 2017 May 1;38(3):19-20

150. Liccardi G, Calzetta L, Barrile A, Giorgino FM, Sapio C, Rogliani P.

Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals? *J Occup Health.* 2017 May 25;59(3):310-311

151. Braido F, Baiardini I, Alleri P, Bacci E, Barbetta C, Bellocchia M, Benfante A, Blasi F, Bucca C, Busceti MT, Centanni S, Colanardi MC, Contoli M, Corsico A, D'Amato M, Di Marco F, Marco D, Ferrari M, Florio G, Fois AG, Foschino Barbaro MP, Silvia G, Girbino G, Grosso A, Latorre M, Maniscalco S, Mazza F, Mereu C, Molinengo G, Ora J, Paggiaro P, Patella V, Pelaia G, Pirina P, Proietto A, Rogliani P, Santus P, Scichilone N, Simioli F, Solidoro P, Terraneo S, Zuccon U, Canonica GW. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. *Pulm Pharmacol Ther.* 2017 Jun;44:83-87

152. Liccardi G, Calzetta L, Salzillo A, Piccolo A, Pane G, Rogliani P.

Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? *Expert Opin Pharmacother.* 2017 Jun;18(8):833-835

153. Cazzola M, Rogliani P, Aliberti S, Blasi F, Matera MG. An update on the pharmacotherapeutic management of lower respiratory tract infections. *Expert Opin Pharmacother.* 2017 Jul;18(10):973-988

154. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. *Respir Med.* 2017 Aug;129:117-123

155. Calzetta L, Ora J, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. *Respir Med.* 2017 Aug;129:189-198

156. Calzetta L, Matera MG, Braido F, Contoli M, Corsico A, Di Marco F, Santus P, Scichilone N, Cazzola M, Rogliani P.

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. *Pulm Pharmacol Ther.* 2017 Aug;45:148-158

157. Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of Precision Medicine in COPD. *Mol Diagn Ther.* 2017 Aug;21(4):345-355

158. Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F. Acute exacerbations of COPD: risk factors for failure and relapse. *Int J Chron Obstruct Pulmon Dis*. 2017 Sep 8;12:2687-2693
159. Cazzola M, Rogliani P, Calzetta L, Lauro D, Page C, Matera MG. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. *Trends Pharmacol Sci*. 2017 Oct;38(10):940-951
160. Cazzola M, Rogliani P. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. *J Comp Eff Res*. 2017 Oct;6(7):627-636
161. Cazzola M, Rogliani P. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV<sub>1</sub> (1) than long-acting beta-agonists plus inhaled corticosteroids. *Evid Based Med*. 2017 Oct;22(5):183-184
162. Liccardi G, Caminati M, Senna G, Calzetta L, Rogliani P. Anaphylaxis and intimate behaviour. *Curr Opin Allergy Clin Immunol*. 2017 Oct;17(5):350-355
163. Calzetta L, Rogliani P, Mattei M, Alfonsi P, Cito G, Pistocchini E, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. *COPD*. 2017 Oct;14(5):526-532
164. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *COPD*. 2017 Oct;14(5):552-563
165. Calzetta L, Rogliani P, Facciolo F, Rendina E, Cazzola M, Matera MG. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. *Eur J Pharmacol*. 2017 Oct 5;812:147-154
166. Calzetta L, Roncada P, di Cave D, Bonizzi L, Urbani A, Pistocchini E, Rogliani P, Matera MG. Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. *Equine Vet J*. 2017 Nov;49(6):710-717
167. Matera MG, Rogliani P, Zanasi A, Cazzola M. Bronchodilator therapy for chronic cough. *Pulm Pharmacol Ther*. 2017 Dec;47:88-92
168. Contoli M, Corsico AG, Santus P, Di Marco F, Braido F, Rogliani P, Calzetta L, Scichilone N. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine. *COPD*. 2017 Dec;14(6):641-647
169. Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. *Int J Chron Obstruct Pulmon Dis*. 2017 Dec 5;12:3469-3485
170. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonisio G, Zompatori M, Dalpiaz G, Picucchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiol Med*. 2017 Dec 11
171. Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. *Expert Opin Drug Metab Toxicol*. 2017 Dec 27:1-7
172. Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulm Pharmacol Ther*. 2017 Dec 30

173. Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? *Expert Rev Respir Med*. 2018 Jan;12(1):43-54.
174. Cazzola M, Rogliani P, Matera MG. Long-term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. *Pol Arch Intern Med*. 2018 Jan 31;128(1):4-6.
175. Liccardi G, Calzetta L, Salzillo A, Piccolo A, Apicella G, Rogliani P. Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link? *Pediatr Pulmonol*. 2018 Feb;53(2):128-129.
176. Liccardi G, Calzetta L, Baldi G, Berra A, Billeri L, Caminati M, Capano P, Carpentieri E, Ciccarelli A, Crivellaro MA, Cutajar M, D'Amato M, Folletti I, Gani F, Gargano D, Giannattasio D, Giovannini M, Lombardi C, Schiavo ML, Madonna F, Maniscalco M, Meriggi A, Micucci C, Milanese M, Montera C, Paolocci G, Parente R, Pedicini A, Pio R, Puggioni F, Russo M, Salzillo A, Scavalli P, Scichilone N, Sposato B, Stanziola A, Steinhilber G, Vatrella A, Rogliani P, Passalacqua G; Italian Allergic Respiratory Diseases Task Force. Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. *Clin Mol Allergy*. 2018 Feb 2;16:3
177. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. *Pulm Pharmacol Ther*. 2018 Feb;48:185-194.
178. Rogliani P, Brusasco V, Fabbri L, Ungar A, Muscianisi E, Barisone I, Corsini A, De Angelis G. Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. *Expert Rev Respir Med*. 2018 Feb;12(2):103-112.
179. Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamics profile of reslizumab in asthma. *Expert Opin Drug Metab Toxicol*. 2018 Feb;14(2):239-245.
180. Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P. How does race/ethnicity influence pharmacological response to asthma therapies? *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):435-446.
181. Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. *Expert Opin Drug Saf*. 2018 May;17(5):509-517.
182. Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. *Expert Opin Drug Saf*. 2018 Apr;17(4):429-435.
183. Calzetta L, Matera MG, Rogliani P, Cazzola M. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. *Expert Rev Respir Med*. 2018 Apr;12(4):261-264.
184. Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Picicchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiol Med*. 2018 Apr;123(4):245-253.
185. Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulm Pharmacol Ther*. 2018 Apr;49:20-26.



186. Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG. Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. *Pulm Pharmacol Ther.* 2018 Apr;49:88-94
187. Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P. Beclomethasone dipropionate and formoterol fumarate synergistically interact with hyperresponsive medium bronchi and small airways. *Respir Res.* 2018 Apr 12;19(1):65.
188. Rogliani P, Calzetta L, Cazzola M. Is ICS-LAMA an alternative option to treat patients with COPD? *Lancet Respir Med.* 2018 May;6(5):316-317.
189. Faverio P, De Giacomo F, Sardella L, Fiorentino G, Carone M, Salerno F, Ora J, Rogliani P, Pellegrino G, Sferrazza Papa GF, Bini F, Bodini BD, Messinesi G, Pesci A, Esquinas A. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. *BMC Pulm Med.* 2018 May 15;18(1):70.
190. Liccardi G, Calzetta L, Milanese M, Salzillo A, Manzi F, Ferrari M, Rogliani P. Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link? *COPD.* 2018 May 7:1-2.
191. Liccardi G, Calzetta L, Milanese M, Salzillo A, Apicella G, Matera MG, Rogliani P. Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? *J Allergy Clin Immunol Pract.* 2018 May - Jun;6(3):1093-1094.
192. Liccardi G, Calzetta L, Milanese M, Lombardi C, Savi E, Passalacqua G, Rogliani P. Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy? *Hum Vaccin Immunother.* 2018 Jun 3;14(6):1438-1441.
193. Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. *Expert Opin Drug Saf.* 2018 Jun;17(6):589-596.
194. Rogliani P, Ora J, Di Daniele N, Lauro D. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. *Curr Opin Pharmacol.* 2018 Jun;40:34-38.
195. Cazzola M, Matera MG, Rogliani P, Calzetta L. Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? *Expert Opin Investig Drugs.* 2018 Jul;27(7):573-581.
196. Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. *Pulm Pharmacol Ther.* 2018 Jun;50:28-37.
197. Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. *Biomed Pharmacother.* 2018 Jul;103:1-8.
198. Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M. Emerging antibacterial and antiviral drugs for treating respiratory tract infections. *Expert Opin Emerg Drugs.* 2018 Jul 30:1-15.
199. Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG. Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. *J Vet Pharmacol Ther.* 2018 Aug;41(4):546-554
200. Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2018 Aug;12(8):693-708.

201. Pompeo E, Rogliani P, Cristino B, Fabbi E, Dauri M, Sergiacomi G. Staged unilateral lung volume reduction surgery: from mini-invasive to minimalist treatment strategies. *J Thorac Dis.* 2018 Aug;10(Suppl 23):S2754-S2762.
202. Liccardi G, Calzetta L, Apicella G, Baldi G, Berra A, Califano F, Ciccarelli A, Cutajar M, D'Amato M, De Crescenzo G, Di Maro E, Gargano D, Giannattasio D, nciso G, Lo Schiavo M, Madonna F, Maniscalco M, Montera C, Papa G, Pedicini A, Pio R, Salzillo A, Stanziola A, Rogliani P, Musarra A. Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. *Eur Ann Allergy Clin Immunol.* 2018 Aug 1.
203. Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG. Impact of doxofylline in COPD: A pairwise meta-analysis. *Pulm Pharmacol Ther.* 2018 Aug;51:1-9.
204. Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. *Eur J Pharmacol.* 2018 Aug 5;832:114-119.
205. Serajeddini H, Rogliani P, Mura M. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. *Lung.* 2018 Aug 27.
206. Yoo DK, Zompatori M, Barrile A, Rossi G, D'Amato D, Sergiacomi G, Rogliani P, Mura M. Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. *Respiration.* 2018 Aug 16:1-9.
207. Liccardi G, Calzetta L, Apicella G, Baldi G, Berra A, Califano F, Ciccarelli A, Cutajar M, D'Amato M, De Crescenzo G, Di Maro E, Gargano D, Giannattasio D, nciso G, Lo Schiavo M, Madonna F, Maniscalco M, Montera C, Papa G, Pedicini A, Pio R, Salzillo A, Stanziola A, Rogliani P, Musarra A. Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study. *Eur Ann Allergy Clin Immunol.* 2018 Aug 1.
208. Calzetta L, Rogliani P, Page C, Roncada P, Pistocchini E, Soggiu A, Piras C, Urbani A, Matera MG. Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis. *Equine Vet J.* 2018 Sep;50(5):594-601.
209. Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Metab Toxicol.* 2018 Sep 28.
210. 3: Labor M, Braido F, Bikov A, Lahousse L, Rogliani P, Baiardini I. LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. *Respiration.* 2018 Sep 18:1-12.
211. Liccardi G, Calzetta L, Milanese M, Maniscalco M, Salzillo A, Rogliani P. Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport. *J Allergy Clin Immunol Pract.* 2018 Sep -Oct;6(5):1808-1809.
212. Liccardi G, Calzetta L, Milanese M, Scaglione M, Rogliani P. Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life. *Ann Allergy Asthma Immunol.* 2018 Oct;121(4):512-513.
213. Cazzola M, Rogliani P. Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. *BMJ Evid Based Med.* 2018 Oct;23(5):183-184.

214. Liccardi G, Calzetta L, Milanese M, Scaglione M, Rogliani P. Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life. *Ann Allergy Asthma Immunol.* 2018 Oct;121(4):512-513.
215. Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. *Int J Chron Obstruct Pulmon Dis.* 2018 Oct 4;13:3115-3130.
216. Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. *Expert Opin Pharmacother.* 2018 Oct 25:1-11.
217. Liccardi G, Calzetta L, Salzillo A, Apicella G, Piccolo A, Di Maro E, Rogliani P. Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life? *Eur Ann Allergy Clin Immunol.* 2018 Nov;50(6):283-285
218. Serajeddini H, Rogliani P, Mura M. Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. *Lung.* 2018 Dec;196(6):707-713.
219. Pompeo E, Rogliani P, Atinkaya C, Guerrera F, Ruffini E, Iñiguez-Garcia MA, Peer M, Voltolini L, Caviezel C, Weder W, Opitz I, Cavalli F, Sorge R. Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. *Interact Cardiovasc Thorac Surg.* 2018 Dec 1..
220. Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. *Eur Respir J.* 2018 Dec 13;52(6).
221. Baiardini I, Rogliani P, Santus P, Corsico AG, Contoli M, Scichilone N, Di Marco F, Lessi P, Scognamillo C, Molinengo G, Ferri F, Patella V, Fiorentino G, Carone M, Braido F. Disease awareness in patients with COPD: measurement and extent. *Int J Chron Obstruct Pulmon Dis.* 2018 Dec 17;14:1-11.
222. Liccardi G, Calzetta L, Milanese M, Passalacqua G, Rogliani P. Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. *J Allergy Clin Immunol.* 2019 Apr;143(4):1657-1658.
223. Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2019 Feb 1:1-14
224. Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messori B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network). The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. *Clin Respir J.* 2019 Mar;13(3):166-173.
225. Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. *J Allergy Clin Immunol Pract.* 2019 May - Jun;7(5):1643-1646.
226. Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. *Chest.* 2019 Apr;155(4):758-770.

227. Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. *Respir Med.* 2019 May;151:43-48.
228. Calzetta L, Cazzola M, Matera MG, Rogliani P. Response. *Chest.* 2019 May;155(5):1079-1080.
229. Rogliani P, Cazzola M, Calzetta L. Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. *J Am Coll Cardiol.* 2019 May 7;73(17):2178-2180.
230. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. *Respir Med.* 2019 May 13;153:3-13.
231. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. *Trends Pharmacol Sci.* 2019 May 27.
232. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. *Respir Res.* 2019 May 27;20(1):104..
233. Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. *Pulm Pharmacol Ther.* 2019 Jun;56:39-50.
234. Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? *Expert Opin Drug Metab Toxicol.* 2019 Jun;15(6):517-520.
235. Corsico AG, Braido F, Contoli M, Di Marco F, Rogliani P, Scognamillo C, Olivi I, Santus P, Scichilone N, Lazzaro C. Corrigendum to "Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up" [*Respir. Med.* 153 (2019) 68-75]. *Respir Med.* 2019 Jun 12
236. Puxeddu E, Fraboni D, Cillis G, Cavalli F, Buccisano F, Rogliani P. CD71-Alveolar Macrophages in IPF: a Look Beyond the Borders of the Disease. *Am J Respir Crit Care Med.* 2019 Jul 26
237. Radovanovic D, Contoli M, Marco FD, Sotgiu G, Pelaia G, Braido F, Corsico AG, Micheletto C, Rogliani P, Scichilone N, Sadari L, Santus P, Solidoro P. Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. *COPD.* 2019 Aug;16(3-4):215-226
238. Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. *Multidiscip Respir Med.* 2019 Aug 3;14:25
239. Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. *F1000Res.* 2019 Aug 29;8. pii: F1000 Faculty Rev-1533
240. Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma. *Respir Med.* 2019 Sep;156:47-52
241. Vancheri C, Sebastiani A, Tomassetti S, Pesci A, Rogliani P, Tavanti L, Luppi F, Harari S, Rottoli P, Ghirardini A, Kirchgassler KU, Albera C. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. *Respir Med.* 2019 Sep;156:78-84
242. Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. *Pulm Pharmacol Ther.* 2019 Sep 11;59:101841

243. Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. *Pulm Pharmacol Ther.* 2019 Oct;58:101828
244. Cazzola M, Puxeddu E, Ora J, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. *Mol Diagn Ther.* 2019 Oct;23(5):603-614
245. Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensfentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. *Expert Opin Investig Drugs.* 2019 Oct;28(10):827-833
246. Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. *Pulm Pharmacol Ther.* 2019 Oct 19;59:101855
247. Rogliani P, Sforza M, Calzetta L. The impact of comorbidities on severe asthma. *Curr Opin Pulm Med.* 2019 Oct 21. doi: 10.1097/MCP.0000000000000640
248. Calzetta L, Matera MG, Cazzola M, Rogliani P. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. *Adv Ther.* 2019 Oct 25. doi: 10.1007/s12325-019-01119-w.
249. Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. *Br J Pharmacol.* 2019 Oct 29. doi: 10.1111/bph.14909
250. Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. *Expert Rev Respir Med.* 2019 Nov;13(11):1079-1085.

### CONTRIBUTION IN VOLUME (CHAPTER OR ESSAY)

- Frasca L, Ambrogi V, Rogliani P, Saltini C and Pompeo E (2012).  
Awake Lung Biopsy for Interstitial Lung Disease . Chapter In, "Awake Thoracic Surgery". p. 105-118 , London: Bentham Ebooks, ISBN: 978-1-60805-288-2
- Rogliani P, Ciapri C (2013).  
IL PAZIENTE FUMATORE. In: Breviario Medico. Pavia: Selecta Medica
- Rogliani P, Segreti A, Cazzola M (2014).  
Chapter:15. Adult Cardiac Conditions . In: Richard F. Lockey, MD, Dennis K. Ledford, MD, and With WAO . (a cura di): OXFORD PRESS, Asthma. Comorbidities, Coexisting Conditions, and Differential Diagnosis.
- Mario Cazzola and Paola Rogliani (2015)  
"Inhaled medication: which device for which patient?", in "Controversies in COPD", Edited by Antonio Anzueto, Yvonne Heijdra and John R. Hurst. ERS Monograph, Septmeber 2015

Allegato 2:

<i>A.A.2004- presente</i>	Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, <b>Corso di Laurea Specialistica in Scienze della Riabilitazione</b> , dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2005- presente</i>	Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, <b>Corso di Laurea in Scienze Infermieristiche</b> , dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2006- presente</i>	Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, <b>Corso di Laurea specialistica in Scienze e Tecniche delle attività motorie Preventive ed Adattate</b> , dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2006- presente</i>	Incarico d'insegnamento di Fisiopatologia Respiratoria (modulo), Corso Integrato Patologia Sistemica I, presso il <b>Corso di Laurea in Medicina e Chirurgia</b> , dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A. 2012-2015</i>	Direttore <b>Scuola di Specializzazione in Medicina dello Sport</b> dell'Università degli Studi di Roma "Tor Vergata".
<i>A.A. 2015- presente</i>	Direttore <b>Scuola di Specializzazione in Malattie dell'Apparato Respiratorio</b> dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2000- presente</i>	<b>Attività tutoriale per la formazione scientifica e clinica degli studenti del Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Roma-"Tor Vergata"</b>
<i>A.A.2000- presente</i>	<b>Guida nella elaborazione delle tesi di specializzazione ed attività tutoriale per la formazione scientifica e clinica degli specializzandi della Scuola di Malattie dell'Apparato Respiratorio dell'Università degli Studi di Roma "Tor Vergata"</b>
<i>A.A.2000- presente</i>	Incarico d'insegnamento di Malattie Respiratorie, <b>Scuola di Specializzazione in Endocrinologia e Malattie Metaboliche</b> dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2000- presente</i>	Incarico d'insegnamento di Metodologia Clinica e di Malattie Respiratorie, <b>Scuola di Specializzazione in Malattie dell'Apparato Respiratorio</b> dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2002- presente</i>	Incarico d'insegnamento, <b>Scuola di Specializzazione in Geriatria</b> dell'Università degli Studi di Roma "Tor Vergata"
<i>A.A.2006- presente</i>	Incarico d'insegnamento di Riabilitazione Cardiorespiratoria, <b>Scuola di Specializzazione in Cardiologia</b> dell'Università degli Studi di Roma "Tor Vergata"

- A.A.2006- 2007                    Incarico d'insegnamento di Malattie Respiratorie, **Scuola di Specializzazione in Medicina dello Sport** dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2007- presente                Incarico d'insegnamento di Fisiopatologia Respiratoria, **Scuola di Specializzazione in Chirurgia Toracica** dell'Università degli Studi di Roma "Tor Vergata"
- A.A.2007- presente                Incarico d'insegnamento di Fisiopatologia Respiratoria, **Scuola di Specializzazione in Medicina Interna** dell'Università degli Studi di Roma "Tor Vergata"

#### PARTECIPAZIONE AL COLLEGIO DEI DOCENTI DI DOTTORATO

- A.A. 2006-2011                    **Dottorato di Ricerca "Fisiopatologia Sperimentale e Medicina Molecolare"** Università degli Studi di ROMA "Tor Vergata"
- A.A. 2011-presente                **Dottorato di Ricerca "Medicina Sperimentale e dei Sistemi"** Università degli Studi di ROMA "Tor Vergata".

#### ATTIVITA' DIDATTICA UFFICIALE PRESSO ATENEI ESTERI

- A.A.2009- 2012                    Incarico d'insegnamento di Malattie dell'Apparato Respiratorio, Corso Integrato Patologia Sistemica I, presso il **Corso di Laurea in Medicina e Chirurgia** Università "Nostra Signora del Buon Consiglio", Tirana, Albania

#### ATTIVITA' UFFICIALE PRESSO SOCIETA' EUROPEA (EUROPEAN RESPIRATORY SOCIETY-ERS)

- 2018-2019                         External reviewer of the ERS Assembly 5 "chronic pulmonary disease" (CPD) Dossier

#### ATTIVITA' ISTITUZIONALE d'ATENEIO

- 2013-presente                    Membro del **Presidio Qualità di Ateneo** (PQA), Macroarea di Medicina e Chirurgia, Università degli Studi di ROMA "Tor Vergata".
- 2016-presente                    Membro della **Commissione paritetica** docenti/studenti, Facoltà di Medicina e Chirurgia, Università degli Studi di ROMA "Tor Vergata".
- 2016-presente                    Membro della **Commissione** per la Valorizzazione dei Risultati della Ricerca e per il Trasferimento Tecnologico in composizione '**Brevetti**', Università degli Studi di ROMA "Tor Vergata".

Roma 30/11/2019

Firma

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali (facoltativo)".

